THE LIBRARY / METABOLIC RESEARCH
Retatrutide
An investigational triple receptor agonist
Investigational human trials
ILLUSTRATION · NOT A PRODUCTAn investigational medicine that acts on GIP, GLP-1, and glucagon receptors; it has not been approved for public use.
What it is
Retatrutide is a peptide-based triple receptor agonist being studied by Lilly in clinical trials for obesity, type 2 diabetes, and related conditions.
What the evidence says
Phase 3 trials have reported results, but retatrutide remains investigational. Clinical trial findings must be assessed with the full study data and regulatory review.
What remains uncertain
Its final benefit-risk profile and any approved indications are not established. Products claiming to be retatrutide outside clinical trials are not equivalent to the studied medicine.
Primary sources
This page is for education only. It is not medical advice, a treatment recommendation, or a guide to obtaining or using a peptide. Speak with a qualified clinician about personal health decisions.